Henry Rosevear, MD, discusses the ten things he’d like to see happen in 2017 for the field of urology.
Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
Percutaneous nephrolithotomy in the presence of aspirin appears both effective and safe. In a retrospective review of almost 300 PCNL cases, postoperative hemorrhage was uncommon in patients who continued aspirin preoperatively, said Brandon Otto, MD, at the AUA annual meeting in San Diego.
“Our research shows that the implications of kidney stones may go beyond the discomfort they are so often associated with,” says co-lead author Andrew Rule, MD.
Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.
. Prescribers should know that the FDA has updated its warnings to say that fluoroquinolones should not be prescribed to patients who have other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections
Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Bilateral replacement of the uterosacral ligaments with a polyvinylidene fluoride (PVDF) mesh (DynaMesh, FEG Textiltechnik mbH) is more effective than medical treatment with solifenacin (Vesicare) for achieving continence in women with urgency urinary incontinence (UUI) associated with only minor pelvic organ prolapse, according to the interim results of a prospective, randomized, crossover clinical trial.
After meeting its primary endpoint at 3 months in a prospective, randomized, sham-controlled clinical trial, an intravesical pressure-attenuation balloon (Vesair Bladder Control System, Solace Therapeutics) for treatment of female stress urinary incontinence demonstrated durable efficacy and safety after 12 months of follow-up.
A new laboratory study suggests that a widely available nutritional supplement has potential to become a new treatment for the wide majority of kidney stones. Clinical research is still pending, however, and there are important caveats about the findings.